SNGX

 
Common Stock
Nasdaq
Contact Info
  • 29 Emmons Drive
  • Suite B-10
  • Princeton, NJ 08540

Business Description


Update Company Profile
 
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Latest Report Sep 30, 2017 10-Q
CIK 0000812796
Fiscal Year End 12/31
OTC Marketplace Not Available
Profile Data
SIC - Industry Classification Not Available
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Service Providers
Accounting/Auditing Firm
EisnerAmper LLP
101 West Avenue
P.O. Box 458
Jenkintown, PA, 19046
United States
 
Securities Counsel
Duane Morris LLP
1540 Broadway
New York, NY, 10036-4086
United States
 
Investor Relations Firm

Not Available
Company History
  • Formerly=DOR BioPharma, Inc. until 9-2009
  • Formerly=Endorex Corp. until 12-01
  • Formerly=ImmunoTherapeutics, Inc. until 9-96
SNGX Security Details Other Company Securities
Share Structure
Market Value1 $12,419,214 a/o Nov 22, 2017
Authorized Shares 10,000,000 a/o Sep 30, 2016
Outstanding Shares 5,723,140 a/o Aug 07, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value Not Available
Shareholders
Shareholders of Record 336 a/o Mar 27, 2017
Short Selling Data
Short Interest 98,469 (92.79%)
Nov 30, 2016
Significant Failures to Deliver No

1Market Value calculated only for respective security